A leading antibody innovation powerhouse

We are a leading international biotechnology company with the ambition to continue to improve the lives of patients with cancer by creating and developing innovative antibody products that will transform the treatment of cancer.

By 2025, our vision is that our own product will have transformed cancer treatment and we will have a robust pipeline of next-generation antibodies.

Genmab (DKK):
Genmab ADS (USD):

View Stock Information

Investor Relations Overview

Creating value by turning science into medicine

Our ambition is to develop drug candidates that have the potential to transform cancer treatment. We do so by leveraging the success of our partnered assets and continuing to invest in our novel proprietary pipeline and technology platforms.

Founded in Copenhagen, Denmark in 1999, Genmab A/S’s ordinary shares are listed on the Nasdaq Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Genmab’s American Depositary Shares issued under the ADR Program are listed in the U.S. on the Nasdaq Global Select Market under the ticker symbol GMAB, and the shares are included in the NASDAQ Biotechnology Index (Nasdaq: NBI).

Genmab’s First Nine Months 2021 Financial Results

On November 10, Genmab announced financial results for the first nine months of 2021.

View Report | View Presentation | Watch On-Demand Webcast

Latest news

    See all news

    Events and presentations

    See all events

    • Financial Reports

      Search and read Genmab’s most recent and previous financial reports.

      View our reports

    • SEC Filings

      See our statements, reports, and other forms submitted to the U.S. Securities and Exchange Commission (SEC).

      Start here

    • Corporate Social Responsibility

      We are committed to being a sustainable and socially responsible biotech company.

      Learn about our CSR

    • Our Science

      Our passion for innovation is driven by data and rooted in science.

      Learn about our expertise

    • The Pipeline

      See the results of our innovation that is driven by data.

      Explore the pipeline

    • Governance Overview

      Our commitment to corporate governance is based on ethics and integrity.

      See our commitment

    Load more

    Investor inquiries

    Our aim is to deliver reliable and transparent information to our shareholders. If you have questions about Genmab, our products or other relevant shareholder information, please use the information below to contact us. We will handle your personal data in accordance with our Privacy Policy.

    • Marisol Peron

      Senior Vice President, Global Communications & Investor Relations

      Telephone: + 1 609 524 0065

      777 Scudders Mill Road
      Plainsboro, NJ 08536

    • Andrew Carlsen

      Vice President,
      Head of Investor Relations

      Telephone: +45 3377 9558

      Kalvebod Brygge 43
      1560 Copenhagen V

    • Examine key figures

      See snapshots of our balance sheets,
      cash flow and other statements

      View our key figures

    • Visit the investor library

      Access our financial reports, webcasts, presentations and more

      Visit our download library

    • Stay informed

      Sign up to receive email alerts with
      our latest news

      Start here

    You are now leaving to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.